Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Axsome Thera (AXSM)

Axsome Thera (AXSM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,997,770
  • Shares Outstanding, K 51,153
  • Annual Sales, $ 638,500 K
  • Annual Income, $ -183,170 K
  • EBIT $ -160 M
  • EBITDA $ -150 M
  • 60-Month Beta 0.43
  • Price/Sales 13.16
  • Price/Cash Flow N/A
  • Price/Book 93.79

Options Overview Details

View History
  • Implied Volatility 59.84% (+2.38%)
  • Historical Volatility 32.52%
  • IV Percentile 97%
  • IV Rank 69.87%
  • IV High 73.08% on 04/10/25
  • IV Low 29.12% on 01/22/26
  • Expected Move (DTE 20) 13.43 (8.59%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 284
  • Volume Avg (30-Day) 780
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 20,246
  • Open Int (30-Day) 21,157
  • Expected Range 142.92 to 169.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.78
  • Number of Estimates 8
  • High Estimate -0.41
  • Low Estimate -1.27
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +2.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
152.28 +2.67%
on 03/24/26
169.11 -7.54%
on 03/10/26
-7.54 (-4.60%)
since 02/27/26
3-Month
148.13 +5.55%
on 12/30/25
191.50 -18.36%
on 01/22/26
+4.30 (+2.83%)
since 12/26/25
52-Week
86.99 +79.73%
on 04/09/25
191.50 -18.36%
on 01/22/26
+34.58 (+28.40%)
since 03/27/25

Most Recent Stories

More News
Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 156.35 (-4.82%)
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 156.35 (-4.82%)
Axsome: Q4 Earnings Snapshot

Axsome: Q4 Earnings Snapshot

AXSM : 156.35 (-4.82%)
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Total 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% year-over-year growth   AUVELITY ® 4Q and full year 2025 net...

AXSM : 156.35 (-4.82%)
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 156.35 (-4.82%)
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders,...

AXSM : 156.35 (-4.82%)
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 156.35 (-4.82%)
MoneyShow Top Picks 2026: Axsome Therapeutics Inc. (AXSM)

Axsome Therapeutics Inc. (AXSM) is a name we started to follow just as the market was going over the falls in early 2025, advises Mike Cintolo, chief investment strategist at Cabot Wealth Network.

AXSM : 156.35 (-4.82%)
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia

NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 156.35 (-4.82%)
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively  AUVELITY ® preliminary...

AXSM : 156.35 (-4.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.

See More

Key Turning Points

3rd Resistance Point 169.97
2nd Resistance Point 166.93
1st Resistance Point 161.64
Last Price 156.35
1st Support Level 153.31
2nd Support Level 150.27
3rd Support Level 144.98

See More

52-Week High 191.50
Last Price 156.35
Fibonacci 61.8% 151.58
Fibonacci 50% 139.24
Fibonacci 38.2% 126.91
52-Week Low 86.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.